ALLO Allogene Therapeutics Inc.

22.71
-0.69  -3%
Previous Close 23.41
Open 23.03
Price To Book 4.47
Market Cap 2,769,006,224
Shares 121,902,101
Volume 602,281
Short Ratio
Av. Daily Volume 656,659
Stock charts supplied by TradingView

NewsSee all news

  1. Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

    Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy SOUTH SAN FRANCISCO, Calif. and

  2. Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell

  3. Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for

  4. Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell

  5. Allogene Therapeutics Reports Third Quarter 2019 Financial Results

    Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM)Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) with Data Expected in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated in 2020.
UCART19 (PALL)
Acute lymphoblastic leukemia (ALL)
Phase 1 trial ongoing.
UCART19 - CALM
Refractory B-cell Acute Lymphoblastic Leukaemia
Phase 1/2 trial initiated 3Q 2019.
ALLO-715
Multiple myeloma
Phase 1 initial data due 1H 2020.
ALLO-501 - ALPHA
Non-Hodgkin lymphoma (NHL)
Phase 1 trial to commence 2H 2020.
ALLO-715 with nirogacestat
Multiple myeloma

Latest News

  1. Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

    Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy SOUTH SAN FRANCISCO, Calif. and

  2. Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell

  3. Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for

  4. Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell

  5. Allogene Therapeutics Reports Third Quarter 2019 Financial Results

    Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM)Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) with Data Expected in

  6. Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

    Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus

  7. Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

    Collaboration Will Evaluate Charge-altering Releasable Transporter System for mRNA Delivery to T CellsResearch Will Be Led by Stanford Researchers Robert Waymouth, Ph.D., Paul Wender, Ph.D. and Ronald Levy, M.D. SOUTH

  8. Allogene Therapeutics Announces September 2019 Investor Conference Schedule

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies